Literature DB >> 25946212

Failure rate: Why many cancer drugs don't receive FDA approval, and what can be done about it.

Carrie Printz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25946212     DOI: 10.1002/cncr.28994

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  5 in total

1.  DIGREM: an integrated web-based platform for detecting effective multi-drug combinations.

Authors:  Minzhe Zhang; Sangin Lee; Bo Yao; Guanghua Xiao; Lin Xu; Yang Xie
Journal:  Bioinformatics       Date:  2019-05-15       Impact factor: 6.937

Review 2.  Patient-centric trials for therapeutic development in precision oncology.

Authors:  Andrew V Biankin; Steven Piantadosi; Simon J Hollingsworth
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

3.  The Impact of Early-Phase Trial Design in the Drug Development Process.

Authors:  Mark R Conaway; Gina R Petroni
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

4.  A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.

Authors:  Corey Saba; Melissa Paoloni; Christina Mazcko; William Kisseberth; Jenna H Burton; Annette Smith; Heather Wilson-Robles; Sara Allstadt; David Vail; Carolyn Henry; Susan Lana; E J Ehrhart; Brad Charles; Michael Kent; Jessica Lawrence; Kristine Burgess; Antonella Borgatti; Steve Suter; Paul Woods; Ira Gordon; Patricia Vrignaud; Chand Khanna; Amy K LeBlanc
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

5.  Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician.

Authors:  Shing M Lee; Nolan A Wages; Karyn A Goodman; A Craig Lockhart
Journal:  JCO Precis Oncol       Date:  2021-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.